The second phase I/II dose-finding clinical trial, conducted in a similar population with long-standing T1D, was aimed to establish the optimum dose of IL-2 (ranged from 0.33 × 106 to 3 × 106 IU/day) for induction of Tregs with a 5-day course in 24 patients [26]. Here, IL2 is linked to type 1 diabetes mellitus.